| 7.31 0.09 (1.25%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.97  |
1-year : | 11.06 |
| Resists | First : | 8.53 |
Second : | 9.47 |
| Pivot price | 8.04 |
|||
| Supports | First : | 7.01 |
Second : | 5.84 |
| MAs | MA(5) : | 7.55 |
MA(20) : | 8.01 |
| MA(100) : | 7.58 |
MA(250) : | 9.74 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 8.1 |
D(3) : | 18.2 |
| RSI | RSI(14): 42.4  |
|||
| 52-week | High : | 17.44 | Low : | 6.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ACET ] has closed above bottom band by 19.7%. Bollinger Bands are 56.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.56 - 7.6 | 7.6 - 7.64 |
| Low: | 6.91 - 6.97 | 6.97 - 7.01 |
| Close: | 7.23 - 7.31 | 7.31 - 7.38 |
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Fri, 05 Jun 2026
BPAS - Adicet Bio, Inc. - Common Stock (Nasdaq:ACET) Stock Quote - FinancialContent
Fri, 05 Jun 2026
BPAS - FinancialContent
Thu, 04 Jun 2026
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference - The Globe and Mail
Thu, 28 May 2026
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Yahoo Finance
Mon, 25 May 2026
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade - Yahoo Finance
Wed, 20 May 2026
Adicet Bio (ACET) updates 10-K to confirm effective 2025 controls - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 63.5 (%) |
| Shares Short | 588 (K) |
| Shares Short P.Month | 598 (K) |
| EPS | -13.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.5 % |
| Return on Equity (ttm) | -72.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -11.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -91 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.53 |
| PEG Ratio | 0 |
| Price to Book value | 0.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|